From The Cochrane Library, Issue 3, 2003. Oxford: Update Software Ltd. All rights reserved.

Isoniazid for preventing tuberculosis in non-HIV infected persons (Cochrane Review)

Smieja MJ, Marchetti CA, Cook DJ, Smaill FM

ABSTRACT

Order full review
View and/or submit comments
What's new in this issue
Search abstracts
Browse alphabetical list of titles
Browse by Review Group

A substantive amendment to this systematic review was last made on 21 November 1998. Cochrane reviews are regularly checked and updated if necessary.

Background: Although isoniazid (INH) is commonly used for treating tuberculosis (TB), it is also effective as preventive therapy.

Objectives: The objective of this review was to estimate the effect of 6 and 12 month courses of INH for preventing TB in HIV-negative people at increased risk of developing active TB.

Search strategy: We searched the Cochrane Infectious Diseases Group trials register, the Cochrane Controlled Trials Register, Medline, Embase and reference lists of articles. We hand-searched Science Citation Index and Index Medicus.

Selection criteria: Randomised trials of INH preventive therapy for 6 months or more compared with placebo. Follow-up for a minimum of 2 years. Trials enrolling patients with current or previously treated active TB, or with known HIV infection, were excluded. Criteria were applied by two reviewers independently.

Data collection and analysis: Trial quality was assessed by two reviewers independently, and data extracted by one reviewer using a standardized extraction form.

Main results: Eleven trials involving 73,375 patients were included. Trials were generally of high quality. Treatment with INH resulted in a relative risk (RR) of developing active TB of 0.40, (95% confidence interval {CI} 0.31 to 0.52), over two years or longer. There was no significant difference between 6 and 12 month courses (RR of 0.44, 95% CI 0.27 to 0.73 for six months, and 0.38, 95% CI 0.28 to 0.50 for 12 months). Preventive therapy reduced deaths from TB, but this effect was not seen for all cause mortality. INH was associated with hepatotoxicity in 0.36% of people on 6 months treatment and in 0.52% of people treated for 12 months.

Reviewers' conclusions: Isoniazid is effective for the prevention of active TB in diverse at-risk patients, and six and 12 month regimens have a similar effect.

Citation: Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.



This is an abstract of a regularly updated, systematic review prepared and maintained by the Cochrane Collaboration. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).

The Cochrane Library is designed and produced by Update Software Ltd.

Update Software Ltd, Summertown Pavilion, Middle Way, Oxford OX2 7LG, UK
(Tel:+44 1865 513902; Fax:+44 1865 516918)

File Reference: AB001363.htm